Share This Page
Drug Price Trends for BUTALBITAL-ASPIRIN-CAFFEINE
✉ Email this page to a colleague
Average Pharmacy Cost for BUTALBITAL-ASPIRIN-CAFFEINE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE | 00781-2270-01 | 0.98268 | EACH | 2025-12-17 |
| BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE | 62135-0433-90 | 0.98268 | EACH | 2025-12-17 |
| BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE | 00527-1552-01 | 0.98268 | EACH | 2025-12-17 |
| BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE | 62135-0433-90 | 0.98014 | EACH | 2025-11-19 |
| BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE | 00781-2270-01 | 0.98014 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Butalbital-Aspirin-Caffeine
Introduction
Butalbital-Aspirin-Caffeine represents a combination drug used primarily for the treatment of tension headaches and migraines. This medication combines a barbiturate (butalbital), an analgesic (aspirin), and a stimulant (caffeine), offering a synergistic approach to pain relief. As therapeutic options evolve and regulatory frameworks tighten, understanding its market dynamics and future pricing trajectory is critical for stakeholders across pharmaceutical companies, healthcare providers, and investors.
Market Overview
Therapeutic Use and Market Demand
The drug targets episodic tension headaches and migraines—common neurological conditions affecting millions globally. The demand remains steady, driven by the prevalence of these conditions, especially among working-age adults and chronic headache sufferers. According to the Global Burden of Disease Study (2020), migraines affect approximately 15% of the population worldwide, with tension headaches being even more widespread.
However, the therapeutic landscape has become more competitive with the advent of novel agents, including calcitonin gene-related peptide (CGRP) inhibitors and other non-barbiturate analgesics. These newer options have contributed to a decline in the use of combination drugs like Butalbital-Aspirin-Caffeine, primarily due to concerns over dependency, side effects, and regulatory scrutiny associated with barbiturates.
Regulatory Environment
In recent years, FDA and international health authorities have imposed stricter regulations on barbiturate-containing medications due to their potential for dependence and abuse. Several formulations have faced scheduling changes or have been restricted to specialist prescriptions. Consequently, market access for Butalbital-Aspirin-Caffeine has been constrained, leading to reduced prescribing volumes in some jurisdictions.
Key Market Players
Principal pharmaceutical companies manufacturing formulations containing Butalbital-Aspirin-Caffeine include Watson Pharmaceuticals, Valeant Pharmaceuticals, and various generic manufacturers. Brand names such as Fiorinal (US) have historically dominated the market but face stiff competition from generics.
Market Challenges
- Regulatory Restrictions: Heightened controls on barbiturate-containing products limit marketing and distribution, impacting market growth.
- Safety Concerns: Side effects associated with barbiturates, such as dependence, sedation, and respiratory depression, have led to preferential prescribing of newer agents.
- Market Penetration: Reduced prescriber confidence and patient preferences for non-barbiturate options have diminished market share.
- Generic Competition: A saturated market with numerous generics has exerted downward pressure on prices.
Market Size and Revenue Trends
Based on historical data, the global market for combination headache medications was valued at approximately USD 500 million in 2018. Given recent regulatory adjustments and declining prescription rates, an average compound annual growth rate (CAGR) of -2% over the next five years is projected, reflecting a contraction driven by diminished demand and market withdrawal of some formulations.
North American markets hold the largest share, driven by higher prescription rates, while European and Asian markets are experiencing variable penetration due to regulatory and cultural prescribing differences.
Price Trends and Projections
Historical Price Movements
The average wholesale price (AWP) for branded Fiorinal ranged from USD 50 to USD 70 per package in the US, with generic equivalents selling at a discount of approximately 20-30%. Over the past decade, prices have declined marginally due to increased generic competition and regulatory pressures.
Factors Influencing Future Pricing
- Generic Market Penetration: Increased generics will continue to suppress prices, especially in mature markets.
- Regulatory Restrictions: Stricter scheduling may lead to shortages or increased distribution costs, potentially inflating prices temporarily.
- Manufacturing Costs: Raw material prices for aspirin and caffeine are relatively stable, but stricter quality controls could increase manufacturing expenses.
- Market Demand: Diminishing demand will impose downward price pressure, particularly as prescribers shift towards newer, safer alternatives.
Price Projection (2023-2028)
Given current trends, the average price of Butalbital-Aspirin-Caffeine formulations is expected to decline at a CAGR of approximately 3-4% over the forecast period. Specifically:
- Short-term (2023-2025): Prices may stabilize or slightly decline due to inventory adjustments post-regulatory changes.
- Medium-term (2026-2028): Further price decreases as market penetration by generics solidifies, with possible temporary upward blips amid supply chain disruptions or regulatory shifts.
Projected average retail prices are anticipated to range between USD 15-25 per package by 2028.
Emerging Market Opportunities
Despite challenges, niche markets such as certain European countries with less stringent regulation, or specialized prescriptions for refractory cases, may sustain modest demand. Additionally, compounding pharmacies may offer tailored formulations, gaining fragmented market segments.
Conclusion
The market for Butalbital-Aspirin-Caffeine is experiencing a contraction driven by regulatory scrutiny, safety concerns, and evolving therapeutic preferences. Price projections suggest continued downward pressure, with declines moderated by manufacturing costs and supply chain dynamics. Stakeholders should consider these factors for strategic positioning, including product diversification and innovation in alternative headache therapies.
Key Takeaways
- The global demand for combination headache medications like Butalbital-Aspirin-Caffeine is declining due to regulatory restrictions and safety issues.
- Market size has shrunk, with an average annual decline of approximately 2-4%, primarily in mature markets.
- Prices are expected to decrease at a CAGR of 3-4% over the next five years, with markeet prices stabilizing around USD 15-25 per package.
- Competitive pressure from generics and newer agents limits pricing power; regulatory changes may further constrain growth.
- Opportunities lie in niche markets, compounding formulations, and developments of safer alternatives.
FAQs
1. What are the primary safety concerns associated with Butalbital-Aspirin-Caffeine?
Barbiturates like butalbital pose risks of dependence, sedation, respiratory depression, and potential for abuse, prompting regulatory restrictions in several jurisdictions.
2. How have regulatory changes affected the availability of Butalbital-Aspirin-Caffeine formulations?
Increased scheduling and prescription controls have limited prescribing, leading to decreased market access and a shift towards alternative therapies.
3. Is there potential for generic manufacturers to influence prices downward further?
Yes, the proliferation of generic versions amplifies price competition, exerting downward pressure on both wholesale and retail prices.
4. What alternatives are currently replacing Butalbital-Aspirin-Caffeine in headache management?
Newer agents such as triptans, CGRP inhibitors, and non-steroidal anti-inflammatory drugs (NSAIDs) are increasingly favored due to better safety profiles.
5. What strategies can stakeholders adopt to mitigate declining market opportunities?
Investing in innovative, safer formulations; expanding into niche markets; or developing combination drugs with improved safety and efficacy profiles can provide new revenue streams.
Sources
[1] Global Burden of Disease Study 2020. The Lancet.
[2] FDA Drug Approvals and Regulations, 2022.
[3] IMS Health Data on Headache Medication Markets, 2019-2022.
[4] Market Research Future Reports on Combination Analgesics, 2022.
More… ↓
